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It is unclear whether the result in the youngest cohort can be
explained by aggressive tumour growth, by too low a sensitivity of
the mammographic test, by too short a follow-up, or by chance. The
absence of any effect so far in the youngest age-group corresponds
with the early results of the age-group 40-49 at entry in the Health
Insurance Plan (HIP) trial. 5 years after the HIP screening
programme had begun, the number of breast cancer deaths was 19 in
the study group and 20 in the control group (RR = 0.95).3 10 years
after the start the RR was 42/54 (0 - 78), and 14 years after the start it
was 46/61 (0-75). Nevertheless the HIP investigators hesitated to
accept this finding as evidence of the effectiveness of screening
under age 50.
In Nijmegen a disease stage classification system according to
mammographical and/or histopathological tumour size was used.
"Advanced stage" means that the axillary lymph nodes were
histologically involved or that the lesion consisted of infiltrative
carcinoma and was at least 2 cm in size. In the age-group 35-49 at
diagnosis 38% of 40 screen-detected cases had advanced disease
stage, as opposed to 4 out of the 6 cases in women who did not
participate in the screening programme. According to these figures
a subsequent mortality reduction can be expected in the youngest
age-group.
Finally, attention should be paid to the weak effect of screening on
breast cancer mortality in the oldest age-group. It is assumed that
breast cancer grows rather slowly in this group.5,6 As a
consequence, the lead-time should be very long, and a strong effect
could be expected after a longer period of follow-up. The odds ratio
for the birth cohort born before 1910 is now only 0 - 81. Maybe this
RR estimate is weak because of different underlying mortality risks
(independent of any screening effect) in the participating and non-
participating groups. Maybe differences in patient’s delay explain
that the effect was less favourable than expected. And maybe
selective misclassification of the death certificates is another
explanation. Further studies will focus on these potential biases.
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LIFETIME PASSIVE SMOKING AND CANCER RISK
SlR,&mdash;Dr Sandler and colleagues (Feb 8, p 312), in a preliminary
report, describe the relative cancer risk for persons living in
households with 0, 1,2, and 3 or more members who smoke. The
risk increased, both for active and for non-smokers, with the number
of household members who smoked, and Sandler et al suggest that
exposure to ambient smoke in the household might be responsible.
In table I they normalise the odds ratio for cancer risk to unity for
households with no (other) smokers and disregard exposure to
cigarette smoke outside the home. Calculating to two decimal
places, the odds ratios for households with 1 (other) smoking
member are I - 42 for active smokers and 1’ 45 for non-smokers; for
households with 2 (other) smokers the corresponding ratios are 2 - 25
and 2 - 32; and for 3 or more, the ratios are 2 - 42 and 2 . 75. The risk
ratios for active smokers are therefore, within the error limits, the
same as for non-smokers; to simplify the argument, I shall treat
them as identical.
Suppose the average risk of cancer is N from all causes
unconnected with smoking, A from active smoking, and P from
passive smoking. An active smoker is also a passive smoker of his
own ambient cigarette smoke, so the total cancer risk for active
smokers in households with no other smoker is N+A+P; in
households with 1 other smoker the risk is N+A+2P. For non-
smokers, the corresponding risks are N and N + P. Because the data
of Sandler et al imply that odds ratios (and hence the ratios of
relative risks) are virtually identical we require that
(N+A+2P)/(N+A+P)=(N+P)/N. In other words A+P=0. This
same relation is obtained from relative risks in households with 2
and with 3 or more (other) smokers. A multiplicative model, in
which the cancer risk in, for example, an active smoker in a
household with no other smokers is of the general form,
N(1+A+P), where A and P are now proportional to the
concentration of effective carcinogens in active and passive
smokers, respectively, also yields the same equality.
The relation A+P=0 leaves us with three possible
interpretations:
(1) Active and passive smoking are both non-carcinogenic
(A = P = 0). (2) Active smoking is carcinogenic and passive smoking
is prophylactic (A= -P). (3) Active smoking is prophylactic and
passive smoking is carcinogenic (P = - A).
The statistical uncertainty in Sandler’s table I is large enough to
permit slightly less paradoxical inferences, but let us pursue the
unthinkable a little further.
Three randomised controlled intervention trials (the Oslo study,’ 1
the Whitehall study2 and MRFIT3) provide a direct
epidemiological test of the hypothesis that giving up active smoking
reduces the risk of cancer. In the "intervention" (low-smoking)
groups in these three trials together there were (including
registrations as well as deaths in the Whitehall study2) 149 cancers
in a combined entry population of 7746 (1-92%); while in the
relatively high-smoking control groups there were 121 cancers in
7797 ( 1  55&deg;7oj. From the orthodox viewpoint-namely, active
smoking causes at least 30% of all cancers-these findings are as
paradoxical as the inferences from Sandler’s study. We might just be
able to postulate complicated, though implausible, causal models to
account for Sandler and colleagues’ table I, or we may put those
results on one side because of their preliminary character. It is more
difficult to evade the implication of the methodologically reputable
randomised trials: active cigarette smoking has little or no net
carcinogenic action.
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SIR,-Dr Sandler and colleagues’ paper on the cumulative effects
of lifetime passive smoking on cancer risk appears seriously flawed.
They compared 518 out of a total of 740 cancer patients aged 15-59
from a hospital-based tumour registry, with 518 controls of the same
age, sex, and race. 309 controls were friends or acquaintances of the
patients and 209 were randomly selected by systematic telephone
sampling. Results are presented for 369 (70%) cases and 409 (79%)
controls. Apart from death before the subjects could be contacted
and refusal, only those persons who had "lived with both natural
parents for most of the first ten years of life" were analysed. We are
told that they supplied information about the smoking habits of
their spouse and parents. Presumably, they also supplied
information about their own smoking.
The results are shown in three tables, only one of which
differentiates between active and passive smoking, and none of
which differentiates between sex, age, and race. The belief that
these factors do not matter because they were matched for is
unsound. The reader has no idea how differences between those
867
initially chosen and those finally analysed could have influenced the
results. Moreover, as soon as the groups are stratified by active
smokers and never smokers, the matching is broken. Until the
results have been presented for non-smokers by age, sex, and race no
conclusions can be drawn.
Furthermore the truncated age group (15-59 years) has resulted
in an unrepresentative selection of cancer cases. Even so, the
distribution by cancer site seems strange: there were 62 (17%)
cancers of the cervix uteri but only 19 (5%) cancers of the
respiratory tract and 48 (13%) breast cancers. The trend in cancer
risk from multiple household exposures to cigarette smoke is least
impressive for cancer of the respiratory system, where an effect
might be expected to be greatest, and most striking for leukaemia
and lymphoma where any biological explanation is, to say the least,
obscure. The most extraordinary finding appears to have been the
very similar trends in cancer risk with number of household
members who smoke irrespective of whether the cases smoked or
not. Indeed, Sandler and colleagues’ publication on the same
material in the American-7ournal of Epidemiology (1985; 121: 37-48)
shows that the effect of passive smoking on cancer risk appears to
have been greater than the effect of active smoking.
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**These letters have been shown to Dr Sandler and colleagues,
whose reply follows.-ED. L.
SIR,-Professor Burch presents an algebraic rearrangement ofour
data that suggests that smoking is protective. His approach assumes
that childhood and adulthood exposures are interchangeable. As we
indicated in our paper, the apparently linear trends in table I
simplify a complex set of relationships. Our data illustrate that
childhood and adulthood exposures may contribute independently
to cancer risk in adulthood, but this does not imply that these two
exposures are equivalent. Data we present elsewhere suggest the
two risks may, in fact, be different (ref 1, and unpublished). As
shown in the accompanying expansion of table II, the odds ratio
associated with passive exposure only as an adult was 1 - 8 for
non-smokers but only 1 - 2 for active smokers (not equal, as Burch’s
analysis requires). For childhood exposures, the opposite was true:
the odds ratio was 1 - 9 for smokers and 1 - 3 for non-smokers. Thus,
passive exposure in childhood seems to have its greatest effect
among persons later exposed to a carcinogen (their own smoking),
while passive exposure in adulthood has its largest effect among
persons not actively exposed. In short, our data do not support the
simplified biological assumptions Burch requires for his analysis.
Dr Higgins raises concern about possible biases in the study and
requests additional data. The information he seeks is provided in a
paper he cites. As explicitly stated in both papers, there was no
confounding by the variables mentioned by Higgins. The
OVERALL CANCER RISK FROM HOUSEHOLD EXPOSURE TO CIGARETTE
SMOKE IN CHILDHOOD AND ADULTHOOD
I I I
*Exposure to smoking mother, father, or other household member during childhood.
t Exposure to smoking spouse.
significant differences between risk with specified exposure and no exposure (p<0 05).
’p=O’051.
Statistical1y significant linear trend: no exposure, exposure in only one time period,
exposure in both time periods (X’ for trend, p<0’0t).
"truncated" age group was chosen because a primary aim of our
study was to evaluate effects of mothers’ smoking. Since few women
smoked before 1920, we studied cases who were younger than age 60
in 1980. It will be several years before cancer risk associated with
mothers’ smoking can be evaluated for older persons. The
distribution of cancer sites studied resulted from methodologic
decisions and hospital referral patterns which were discussed in the
papers. Nonetheless this group was not preselected on the basis of
any prior hypothesis, and it is not easy to see how inclusion of more
cancers that are "unrelated" to cigarette smoking would lead to an
inflated overall cancer risk from passive smoking.
Higgins cites our finding of a leukaemia effect as one for which
"any biological explanation is, to say the least, obscure". On the
contrary, cigarette smoke contains chemicals known to be
leukaemogenic, and has been associated with increased leukaemia
risk in many,2-5 although not all6 studies. Some of these studies find
an apparent dose-response, especially for non-lymphocytic
leukaemias.2,3,5 The 40-50% increase in leukaemia risk among
smokers is much smaller than that reported for other sites such as
the lung, which may account for the lack of interest in smoking and
leukaemia. Experimental and biochemical data from a variety of
sources (refs 7 and 8, and discussed in our papers) are also consistent
with a possible association between leukaemia risk and exposure to
cigarette smoke.
There is one final point. Our study was not designed to compare
the effects of active and passive smoking. Our method of choosing
friend controls inadvertently matched for active smoking, which
erases the possibility of observing an effect due to active smoking.
Higgins’ comparison of the effects of active and passive smoking is
not meaningful in our data.
The questions raised by Burch and Higgins do not persuade us
that our study is "seriously flawed". We stress the need for
additional studies and strongly urge investigators to consider that
the range of possible effects from active and passive exposure to
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REDUCED RESPONSE OF URAEMIC BLEEDING TIME
TO REPEATED DOSES OF DESMOPRESSIN
SIR,-Treatment with desmopressin (1-deamino-8-D-arginine
vasopressin, DDAVP) shortens prolonged bleeding times in
patients with von Willebrand disease, platelet defects,2 and
uraemia,3-5 and in healthy subjects.2 The bleeding time correction
by desmopressin has been attributed to the raising of plasma
concentrations of high-molecular-weight forms of factor VIII
(FVIII) related antigen and von Willebrand factor (vWF) activity.6
In uraemia FVIII-vWF concentrations are normal to high even
before desmopressin; here, the presence of abnormal multimers
may explain why normal multimers, provided via desmopressin orcryopreCIpitate -7 are effective.
Published experience with desmopressin in uraemia is limited to
short-term responses. When we gave cryoprecipitate (30 ml/kg) in
